D.E. Shaw & Co’s KALA BIO KALA Stock Holding History

D.E. Shaw & Co’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6	Closed	-$133K	–	4121
2020 Q1	$133K	Hold	6	–	–	﹤0.01%	3743
2019 Q4	$56K	Buy	+6	New	+$57.9K	﹤0.01%	3897

Other funds holding KALA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

D.E. Shaw & Co's KALA Position: Q2 2022 in Review

D.E. Shaw & Co sold out of KALA BIO (KALA) in Q2 2022, closing a stake of 12 shares — an estimated $41K sold.

D.E. Shaw & Co first reported a position in KALA in Q1 2018 and held it in 11 quarters. The position peaked at $1.81M in Q2 2020. 63 funds tracked by Wall St. Rank hold KALA as of Q2 2022.

D.E. Shaw & Co reported no remaining KALA BIO position as of Q2 2022 after selling out during the quarter.
D.E. Shaw & Co sold 12 KALA BIO shares in Q2 2022, an estimated $41K.
D.E. Shaw & Co first reported a position in KALA BIO in Q1 2018 and held it in 11 quarters.
D.E. Shaw & Co's KALA BIO position peaked at $1.81M in Q2 2020.
63 funds tracked by Wall St. Rank held KALA BIO as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.